A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/365 (2006.01) A61K 31/00 (2006.01) A61K 31/341 (2006.01)
Patent
CA 2254061
This invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day administration, said composition comprising a cyclooxygenase-2 inhibiting compound characterized by high potency, a long half life and a high degree of specificity for inhibiting cyclooxygenase-2 in preference to cyclooxygenase-1. Such a compound is exemplified by 3-phenyl- 4-(4-methylsulfonyl)phenyl-2-(5H)-furanone of formula: Image In one aspect, this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising 5 to 125 mgs of the above-mentioned compound. The invention is also directed to a method of treating cyclooxygenase-2 mediated diseases comprising the once a day oral administration of 5 to 125 mgs of the above-mentioned compound. The invention is also directed to the use of the above-mentioned compound in the manufacture of a medicament containing 5 to 125 mgs of said compound for once a day administration for the treatment of cyclooxygenase-2 mediated diseases.
Composition pharmaceutique pour le traitement de maladies dont le médiateur est la cyclooxygénase-2, cette composition étant adaptée à une administration quotidienne monodose et comprenant un composé inhibiteur de la cyclooxygénase-2 caractérisé par un potentiel élevé, une demi-vie prolongée et un degré de spécificité élevé pour inhiber la cyclooxygénase-2 plutôt que la cyclooxygénase-1. Ce composé peut être par exemple 3-phényl-4-(4-méthylsulfonyl)phényl)-2-(5H)-furanone. Dans son premier aspect l'invention concerne une composition pharmaceutique pour le traitement des maladies à médiateur cyclooxygénase-2, cette composition étant adaptée à une administration quotidienne monodose par voie orale et comprenant 5 à 125 mg du composé décrit ci-dessus. Le second aspect porte sur une méthode de traitement des maladies à médiateur cyclooxygénase-2 comprenant l'administration orale journalière de 5 à 125 mg du composé décrit ci-dessus. L'invention porte en outre sur l'utilisation du composé décrit ci-dessus dans la fabrication d'un médicament contenant 5 à 125 mg dudit composé, destiné à une administration journalière monodose pour le traitement des maladies à médiateur cyclooxygénase-2.
Ehrich Elliot
Gertz Barry
Hancock Bruno
Winters Conrad
Merck & Co. Inc.
Merck Frosst Canada Inc.
Merck Frosst Company
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Compositions for a once a day treatment of cyclooxygenase-2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for a once a day treatment of cyclooxygenase-2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for a once a day treatment of cyclooxygenase-2... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1526183